The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AMAZON COM INC | COM | 023135106 | 226 | 113 | SH | SOLE | 113 | 0 | 0 | ||
| INNOVATE BIOPHARMACEUTICLS I | COM PAR | 45782F105 | 134 | 19,610 | SH | SOLE | 19,610 | 0 | 0 | ||
| VANGUARD GROUP | DIV APP ETF | 921908844 | 213 | 1,919 | SH | SOLE | 1,919 | 0 | 0 | ||
| VANGUARD INTL EQUITY INDEX F | TT WRLD ST ETF | 922042742 | 5,838 | 76,983 | SH | SOLE | 76,983 | 0 | 0 | ||
| VANGUARD TAX MANAGED INTL FD | FTSE DEV MKT ETF | 921943858 | 19,455 | 449,622 | SH | SOLE | 449,622 | 0 | 0 | ||